Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease
Status:
COMPLETED
Trial end date:
2024-09-07
Target enrollment:
Participant gender:
Summary
This is a randomized double-blind, placebo-controlled, investigator-initiated trial that compares Colchicine 0.5mg/day with placebo, among patients with stable CAD. Subjects will be educated to maintain medication compliance with other prescribed medications.
Phase:
PHASE4
Details
Lead Sponsor:
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center